Skip to main content

07-05-2019 | Multiple sclerosis | Video

AAN 2019: Amyloid PET may predict cognitive decline in patients with MS

Jordi Matias-Guiu summarises the findings of their prospective study investigating the use of amyloid positron emission tomography to identify multiple sclerosis patients likely to experience cognitive impairment (3:10).

Funding for independent interviews at AAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.